Formulation, stabilisation and encapsulation of bacteriophage for phage therapy

Advances in Colloid and Interface Science

Volumn 249, Issue , 2017, Pages 100-133

  Malik, Danish J ^a   Sokolov, Ilya J ^a   Vinner, Gurinder K ^a   Mancuso, Francesco ^a   Cinquerrui, Salvatore ^a   Vladisavljevic, Goran T ^a   Clokie, Martha R J ^b   Garton, Natalie J ^b   Stapley, Andrew G F ^a   Kirpichnikova, Anna ^c  

^a LOUGHBOROUGH UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF LEICESTER   (United Kingdom)

^c LIVERPOOL HOPE UNIVERSITY   (United Kingdom)

Author keywords

Antibiotic resistance; Bacteriophage; Encapsulation; Phage therapy; Pharmacodynamics

Indexed keywords

ANIMALS; ANTIBIOTICS; BACTERIA; DRYING; ENCAPSULATION; LIPOSOMES; NANOPARTICLES; PHARMACODYNAMICS; STABILIZATION; STORAGE (MATERIALS);

ANTIBIOTIC RESISTANCE; CHRONIC INFECTION; MICRO AND NANO-PARTICLE; NANO-ENCAPSULATION; PHAGE THERAPY; PHARMACOKINETICS AND PHARMACODYNAMICS; POLYMERIC MICROPARTICLES; STIMULI-RESPONSIVE SYSTEMS;

BACTERIOPHAGES;

LIPOSOME; NANOPARTICLE;

ANIMAL; ANTIBIOSIS; BACTERIAL INFECTION; BACTERIOPHAGE; BACTERIUM; CHEMISTRY; CLINICAL TRIAL (TOPIC); DRUG FORMULATION; FREEZE DRYING; HUMAN; MICROBIOLOGY; MULTIDRUG RESISTANCE; PATHOGENICITY; PHAGE THERAPY; PHYSIOLOGY; PROCEDURES; VIROLOGY; VIRUS ASSEMBLY;

ANIMALS; ANTIBIOSIS; BACTERIA; BACTERIAL INFECTIONS; BACTERIOPHAGES; CLINICAL TRIALS AS TOPIC; DRUG COMPOUNDING; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FREEZE DRYING; HUMANS; LIPOSOMES; NANOPARTICLES; PHAGE THERAPY; VIRUS ASSEMBLY;

EID: 85021791663     PISSN: 00018686     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cis.2017.05.014     Document Type: Review

References (251)

1. O'Neill, J., Tackling Drug-Resistant Infections Globally: Final Report and Recommendations. Rev Antimicrob Resist, 2016, 1–84, 10.1016/j.jpha.2015.11.005.
2. Moellering, R.C., N Engl J Med 363 (2010), 2377–2379, 10.1056/NEJMp1002530.
3. Liu, Y.Y., Wang, Y., Walsh, T.R., Yi, L.X., Zhang, R., Spencer, J. et al., Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. Lancet Infect Dis 16 (2016), 161–168, 10.1016/S1473-3099(15)00424-7.
4. Coates, A.R., Halls, G., Hu, Y., Novel classes of antibiotics or more of the same?. Br J Pharmacol 163 (2011), 184–194, 10.1111/j.1476-5381.2011.01250.x.
5. Czaplewski, L., Bax, R., Clokie, M., Dawson, M., Fairhead, H., Fischetti, V.A. et al., Alternatives to antibiotics — a pipeline portfolio review. Lancet Infect Dis 16 (2016), 239–251, 10.1016/S1473-3099(15)00466-1.
6. Wittebole, X., De Roock, S., Opal, S.M., A historical overview of bacteriophage therapy as an alternative to antibiotics for the treatment of bacterial pathogens. Virulence 5 (2014), 226–235, 10.4161/viru.25991.
7. Young, R., Gill, J.J., Phage therapy redux — what is to be done?. Science 350 (2015), 1163–1164, 10.1126/science.aad8222.
8. Levin, B.R., Bull, J.J., Population and evolutionary dynamics of phage therapy. Nat Rev Microbiol 2 (2004), 166–173, 10.1038/nrmicro822.
9. Cairns, B.J., Timms, A.R., Jansen, V.A.A., Connerton, I.F., Payne, R.J.H., Quantitative models of in vitro bacteriophage-host dynamics and their application to phage therapy. PLoS Pathog 5 (2009), 1–10, 10.1371/journal.ppat.1000253.
10. Bull, J.J., Gill, J.J., The habits of highly effective phages: population dynamics as a framework for identifying therapeutic phages. Front Microbiol 5 (2014), 1–12, 10.3389/fmicb.2014.00618.
11. Hadas, H., Einav, M., Fishov, I., Zaritsky, A., bateriophage T4 development depends on the physiology of its host Escherichia coli. Microbiology 143 (1997), 179–185.
12. Gill, J.J., Hyman, P., Phage choice, isolation and preparation for phage therapy. Curr Pharm Biotechnol, 11, 2010, 2014.
13. Weber-Dabrowska, B., Jonczyk-Matysiak, E., Zaczek, M., Lobocka, M., Lusiak-Szelachowska, M., Gorski, A., Bacteriophage procurement for therapeutic purposes. Front Microbiol 7 (2016), 1–14, 10.3389/fmicb.2016.01177.
14. Mattila, S., Ruotsalainen, P., Jalasvuori, M., On-demand isolation of bacteriophages against drug-resistant bacteria for personalized phage therapy. Front Microbiol 6 (2015), 1–7, 10.3389/fmicb.2015.01271.
15. Sutherland, I.W., Hughes, K.A., Skillman, L.C., Tait, K., The interaction of phage and biofilms. FEMS Microbiol Lett 232 (2004), 1–6, 10.1016/S0378-1097(04)00041-2.
16. Cornelissen, A., Ceyssens, P.J., T'Syen, J., van Praet, H., Noben, J.P., Shaburova, O.V. et al., The t7-related pseudomonas putida phage φ15 displays virion-associated biofilm degradation properties. PLoS One, 6, 2011, 10.1371/journal.pone.0018597.
17. Pires, D.P., Oliveira, H., Melo, L.D.R., Sillankorva, S., Azeredo, J., Bacteriophage-encoded depolymerases: their diversity and biotechnological applications. Appl Microbiol Biotechnol 100 (2016), 2141–2151, 10.1007/s00253-015-7247-0.
18. Gutiérrez, D., Vandenheuvel, D., Martínez, B., Rodríguez, A., Lavigne, R., García, P., Two phages, phiIPLA-RODI and phiIPLA-C1C, lyse mono- and dual-species staphylococcal biofilms. Appl Environ Microbiol 81 (2015), 3336–3348, 10.1128/AEM.03560-14.
19. Khalifa, L., Brosh, Y., Gelman, D., Coppenhagen-Glazer, S., Beyth, S., Poradosu-Cohen, R. et al., Targeting Enterococcus faecalis biofilms with phage therapy. Appl Environ Microbiol 81 (2015), 2696–2705, 10.1128/AEM.00096-15.
20. Smith, H.W., Huggins, M.B., Shaw, K.M., The control of experimental Escherichia coli diarrhoea in calves by means of bacteriophages. J Gen Microbiol 133 (1987), 1111–1126, 10.1099/00221287-133-5-1111.
21. Nakai, T., Sugimoto, R., Park, K.-H., Matsuoka, S., Mori, K., Nishioka, T. et al., Protective effects of bacteriophage on experimental Lactococcus garvieae infection in yellowtail. Dis Aquat Organ 37 (1999), 33–41.
22. Smith, H.W., Huggins, M.B., Effectiveness of phages in treating experimental Escherichia coli diarrhoea in calves, piglets and lambs. J Gen Microbiol 129 (1983), 2659–2675, 10.1099/00221287-129-8-2659.
23. Atterbury, R.J., Van Bergen, M.A.P., Ortiz, F., Lovell, M.A., Harris, J.A., De Boer, A. et al., Bacteriophage therapy to reduce Salmonella colonization of broiler chickens. Appl Environ Microbiol 73 (2007), 4543–4549, 10.1128/AEM.00049-07.
24. Peltomaa, R., López-Perolio, I., Benito-Peña, E., Barderas, R., Moreno-Bondi, M.C., Application of bacteriophages in sensor development. Anal Bioanal Chem 408 (2016), 1805–1828, 10.1007/s00216-015-9087-2.
25. Ulett, G.C., Totsika, M., Schaale, K., Carey, A.J., Sweet, M.J., Schembri, M.A., Uropathogenic Escherichia coli virulence and innate immune responses during urinary tract infection. Curr Opin Microbiol 16 (2013), 100–107, 10.1016/j.mib.2013.01.005.
26. Debarbieux, L., Leduc, D., Maura, D., Morello, E., Criscuolo, A., Grossi, O. et al., Bacteriophages can treat and prevent Pseudomonas aeruginosa lung infections. J Infect Dis 201 (2010), 1096–1104, 10.1086/651135.
27. Alemayehu, D., Casey, P.G., Mcauliffe, O., Guinane, C.M., Martin, J.G., Shanahan, F. et al., Bacteriophage phiMR299-2 and phiNH-4 can eliminate Psuedomonas aeruginosa in the murine lung and on cystic fibrosis lung airway. MBio 3 (2012), 1–9, 10.1128/mBio.00029-12.Editor.
28. Morello, E., Saussereau, E., Maura, D., Huerre, M., Touqui, L., Debarbieux, L., Pulmonary bacteriophage therapy on pseudomonas aeruginosa cystic fibrosis strains: first steps towards treatment and prevention. PLoS One, 6, 2011, 10.1371/journal.pone.0016963.
29. Capparelli, R., Parlato, M., Borriello, G., Salvatore, P., Iannelli, D., Experimental phage therapy against Staphylococcus aureus in mice. Antimicrob Agents Chemother 51 (2007), 2765–2773, 10.1128/AAC.01513-06.
30. Smith, H.W., Huggins, M.B., Successful treatment of experimental Escherichia coli infections in mice using phage: its general superiority over antibiotics. Microbiology 128 (1982), 307–318, 10.1099/00221287-128-2-307.
31. Singla, S., Harjai, K., Katare, O.P., Chhibber, S., Bacteriophage-loaded nanostructured lipid carrier: improved pharmacokinetics mediates effective resolution of Klebsiella pneumoniae-induced lobar pneumonia. J Infect Dis 212 (2015), 325–334, 10.1093/infdis/jiv029.
32. Chhibber, S., Kaur, S., Kumari, S., Therapeutic potential of bacteriophage in treating Klebsiella pneumoniae B5055-mediated lobar pneumonia in mice. J Med Microbiol 57 (2008), 1508–1513, 10.1099/jmm.0.2008/002873-0.
33. Wills, Q.F., Kerrigan, C., Soothill, J.S., Experimental bacteriophage protection against Staphylococcus aureus abscesses in a rabbit model experimental bacteriophage protection against Staphylococcus aureus abscesses in a rabbit model. Antimicrob Agents Chemother 49 (2005), 1220–1221, 10.1128/AAC.49.3.1220.
34. McVay, C.S., Velásquez, M., Fralick, J.A., Phage therapy of Pseudomonas aeruginosa infection in a mouse burn wound model. Antimicrob Agents Chemother 51 (2007), 1934–1938, 10.1128/AAC.01028-06.
35. Sarker, S.A., Sultana, S., Reuteler, G., Moine, D., Descombes, P., Charton, F. et al., Oral phage therapy of acute bacterial diarrhea with two coliphage preparations: a randomized trial in children from Bangladesh. EBioMedicine 4 (2016), 124–137, 10.1016/j.ebiom.2015.12.023.
36. Donlan, R.M., Costerton, J.W., Biofilms: survival mechanisms of clinically relevant microorganisms. Clin Microbiol Rev. 15 (2002), 167–193, 10.1128/CMR.15.2.167.
37. Hall-Stoodley, L., Costerton, J.W., Stoodley, P., Bacterial biofilms: from the natural environment to infectious diseases. Nat Rev Microbiol 2 (2004), 95–108.
38. Peters, B.M., Jabra-Rizk, M.A., O'May, G.A., William Costerton, J., Shirtliff, M.E., Polymicrobial interactions: impact on pathogenesis and human disease. Clin Microbiol Rev 25 (2012), 193–213, 10.1128/CMR.00013-11.
39. Singla, S., Harjai, K., Raza, K., Wadhwa, S., Katare, O.P., Chhibber, S., Phospholipid vesicles encapsulated bacteriophage: a novel approach to enhance phage biodistribution. J Virol Methods 236 (2016), 68–76, 10.1016/j.jviromet.2016.07.002.
40. Chan, B.K., Abedon, S.T., Bacteriophage and their enzymes in biofilm control. Curr Pharm Des 21 (2015), 85–99.
41. Furusawa, T., Iwano, H., Hiyashimizu, Y., Matsubara, K., Higuchi, H., Nagahata, H. et al., Phage Therapy Is Effective in a Mouse Model of Bacterial Equine Keratitis. Appl Environ Microbiol 82 (2016), 5332–5339, 10.1128/aem.01166-16.
42. Carmody, L.A., Gill, J.J., Summer, E.J., Sajjan, U.S., Gonzalez, C.F., Young, R.F. et al., Efficacy of bacteriophage therapy in a model of Burkholderia cenocepacia pulmonary infection. J Infect Dis 201 (2010), 264–271, 10.1086/649227.
43. Martin, R.M., Cao, J., Brisse, S., Passet, V., Wu, W., Zhao, L. et al., Molecular epidemiology of colonizing and infecting isolates of Klebsiella pneumoniae. mSphere 1 (2016), 1–12, 10.1128/mSphere.00261-16.
44. WHO, Global tuberculosis report. 2016.
45. Jassal, M., Bishai, W.R., Extensively drug-resistant tuberculosis. Lancet Infect Dis 9 (2009), 19–30, 10.1016/S1473-3099(08)70260-3.
46. Russell, D.G., Barry, C.E., Flynn, J.L., Tuberculosis: what we don't know can, and does, hurt us. Science (80-) 328 (2010), 852–856.
47. Nieth, A., Verseux, C., Barnert, S., Süss, R., Römer, W., A first step toward liposome-mediated intracellular bacteriophage therapy. Expert Opin Drug Deliv, 2015, 1–14, 10.1517/17425247.2015.1043125.
48. Nieth, A., Verseux, C., Römer, W., A question of attire: dressing up bacteriophage therapy for the battle against antibiotic-resistant intracellular bacteria. Springer Sci Rev 3 (2015), 1–11, 10.1007/s40362-014-0027-x.
49. Guest, J.F., Ayoub, N., Mcilwraith, T., Uchegbu, I., Gerrish, A., Weidlich, D. et al., Health economic burden that different wound types impose on the UK's National Health Service. BMJ Open, 5, 2015, e009283, 10.1111/iwj.12603.
50. Lindholm, C., Searle, R., Wound management for the 21st century: combining effectiveness and efficiency. Int Wound J 13 (2016), 5–15, 10.1111/iwj.12623.
51. Clinton, A., Carter, T., Chronic wound biofilms: pathogenesis and potential therapies. Lab Med 46 (2015), 277–284.
52. Wiegand, C., Abel, M., Ruth, P., Hipler, U.C., HaCaT keratinocytes in co-culture with Staphylococcus aureus can be protected from bacterial damage by polihexanide. Wound Repair Regen 17 (2009), 730–738, 10.1111/j.1524-475X.2009.00536.x.
53. Peterson, L.R., Review. Squeezing the antibiotic balloon: the impact of antimicrobial classes on emerging resistance. Clin Microbiol Infect Suppl 11 (2005), 4–16, 10.1111/j.1469-0691.2005.01238.x.
54. Lipsky, B.A., Berendt, A.R., Cornia, P.B., Pile, J.C., Peters, E.J.G., Armstrong, D.G. et al., 2012 Infectious Diseases Society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections. Clin Infect Dis 54 (2012), 132–173, 10.1093/cid/cis346.
55. Nale, J.Y., Shan, J., Hickenbotham, P.T., Fawley, W.N., Wilcox, M.H., Clokie, M.R.J., Diverse temperate bacteriophage carriage in Clostridium difficile 027 strains. PLoS One 7 (2012), 1–9, 10.1371/journal.pone.0037263.
56. Curtis, V., Cairncross, S., Effect of washing hands with soap on diarrhoea risk in the community: a systematic review. Lancet Infect Dis 3 (2003), 275–281.
57. Abdulamir, A.S., Sabah, J., Bakar Fatimah, A., Novel approach of using a cocktail of designed bacteriophages against gut pathogenic E. coli for bacterial load biocontrol. Ann Clin Microbiol Antimicrob 13 (2014), 1–11.
58. Yen, M., Cairns, L.S., Camilli, A., Zuckerman, J.N., Rombo, L., Fisch, A. et al., A cocktail of three virulent bacteriophages prevents Vibrio cholerae infection in animal models. Nat Commun, 8, 2017, 14187, 10.1038/ncomms14187.
59. Wall, S.K., Zhang, J., Rostagno, M.H., Ebner, P.D., Phage therapy to reduce preprocessing Salmonella infections in market-weight swine. Appl Environ Microbiol 76 (2010), 48–53, 10.1128/AEM.00785-09.
60. Oliveira, M., Viñas, I., Colàs, P., Anguera, M., Usall, J., Abadias, M., Effectiveness of a bacteriophage in reducing Listeria monocytogenes on fresh-cut fruits and fruit juices. Food Microbiol 38 (2014), 137–142, 10.1016/j.fm.2013.08.018.
61. Hua Zou, W.W., Phage therapy: promising for H. pylori infection. Clin Microbiol Open Access 2 (2013), 10–11, 10.4172/2327-5073.1000112.
62. Kotloff, K.L., Nataro, J.P., Blackwelder, W.C., Nasrin, D., Farag, T.H., Panchalingam, S. et al., Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case-control study. Lancet 382 (2013), 209–222, 10.1016/S0140-6736(13)60844-2.
63. Payne, R.J.H., Jansen, V., Understanding bacteriophage therapy as a density-dependent kinetic process. J Theor Biol 208 (2001), 37–48, 10.1006/jtbi.2000.2198.
64. Tanji, Y., Shimada, T., Fukudomi, H., Miyanaga, K., Nakai, Y., Unno, H., Therapeutic use of phage cocktail for controlling Escherichia coli O157:H7 in gastrointestinal tract of mice. J Biosci Bioeng 100 (2005), 280–287, 10.1263/jbb.100.280.
65. Leung, C.Y., Weitz, J.S., Synergistic elimination of bacteria by phage and the immune system. bioRxiv, 2016, 57927, 10.1101/057927.
66. Smith, H.W., Huggins, M.B., Successful Treatment of Experimental Escherichia coli Infections in Mice Using Phage: its General Superiority over Antibiotics. J Gen Microbiol 128 (1982), 307–318, 10.1099/00221287-128-2-307.
67. Biswas, B., Adhya, S., Washart, P., Paul, B., Trostel, A.N., Powell, B. et al., Bacteriophage therapy rescues mice bacteremic from a clinical isolate of vancomycin-resistant Enterococcus faecium. Infect Immun 70 (2002), 204–210, 10.1128/IAI.70.1.204.
68. Cerveny, K.E., DePaola, A., Duckworth, D.H., Gulig, P.A., Phage therapy of local and systemic disease caused by Vibrio vulnificus in iron-dextran-treated mice. Infect Immun 70 (2002), 6251–6262, 10.1128/IAI.70.11.6251.
69. Barrow, P., Lovell, M., Use of lytic bacteriophage for control of experimental Escherichia coli septicemia and meningitis in chickens and calves. Clin Diagn Lab Immunol 5 (1998), 294–298.
70. Watanabe, R., Matsumoto, T., Sano, G., Ishii, Y., Tateda, K., Sumiyama, Y. et al., Efficacy of bacteriophage therapy against gut-derived sepsis caused by Pseudomonas aeruginosa in mice. Antimicrob Agents Chemother 51 (2007), 446–452, 10.1128/AAC.00635-06.
71. Matsuzaki, S., Yasuda, M., Nishikawa, H., Kuroda, M., Ujihara, T., Shuin, T. et al., Experimental protection of mice against lethal Staphylococcus aureus infection by novel bacteriophage phi MR11. J Infect Dis 187 (2003), 613–624, 10.1086/374001.
72. Tsonos, J., Vandenheuvel, D., Briers, Y., De Greve, H., Hernalsteens, J.P., Lavigne, R., Hurdles in bacteriophage therapy: Deconstructing the parameters. Vet Microbiol 171 (2014), 460–469, 10.1016/j.vetmic.2013.11.001.
73. Wagenaar, J.A., Bergen, M.A.P.V., Mueller, M.A., Wassenaar, T.M., Carlton, R.M., Phage therapy reduces Campylobacter jejuni colonization in broilers. Vet Microbiol 109 (2005), 275–283, 10.1016/j.vetmic.2005.06.002.
74. Andreatti Filho, R.L., Higgins, J.P., Higgins, S.E., Gaona, G., Wolfenden, A.D., Tellez, G. et al., Ability of bacteriophages isolated from different sources to reduce Salmonella enterica serovar enteritidis in vitro and in vivo. Poult Sci 86 (2007), 1904–1909.
75. Stanford, K., Niu, Y.D., Johnson, R., Oral delivery systems for encapsulated bacteriophages targeted at Escherichia coli O157:H7 in feedlot cattle. J Food Prot 73 (2010), 1304–1312.
76. Nale, J.Y., Spencer, J., Hargreaves, K.R., Buckley, A.M., Trzepin, P., Douce, G.R. et al., Bacteriophage combinations significantly reduce Clostridium difficile growth in vitro and proliferation in vivo. Antimicrob Agents Chemother 60 (2016), 968–981, 10.1128/AAC.01774-15.Address.
77. Colom, J., Cano-Sarabia, M., Otero, J., Cortés, P., Maspoch, D., Llagostera, M., Liposome-encapsulated bacteriophages for enhanced oral phage therapy against Salmonella spp. Appl Environ Microbiol 81 (2015), 4841–4849, 10.1128/AEM.00812-15.
78. Colom, J., Cano-Sarabia, M., Otero, J., Aríñez-Soriano, J., Cortés, P., Maspoch, D. et al., Microencapsulation with alginate/CaCO3: a strategy for improved phage therapy. Sci Rep, 7, 2017, 41441, 10.1038/srep41441.
79. Zhang, J.Y., Kraft, B.L., Pan, Y.Y., Wall, S.K., Saez, A.C., Ebner, P.D., Development of an Anti-Salmonella Phage Cocktail with Increased Host Range. Foodborne Pathog Dis 7 (2010), 1415–1419, 10.1089/fpd.2010.0621.
80. Bardina, C., Spricigo, D.A., Cortés, P., Llagostera, M., Significance of the bacteriophage treatment schedule in reducing salmonella colonization of poultry. Appl Environ Microbiol 78 (2012), 6600–6607, 10.1128/AEM.01257-12.
81. Teixeira, A.P., Oliveira, R., Alves, P.M., Carrondo, M.J.T., Advances in on-line monitoring and control of mammalian cell cultures: supporting the PAT initiative. Biotechnol Adv 27 (2009), 726–732, 10.1016/j.biotechadv.2009.05.003.
82. Murthy, K., Engelhardt, R., US 2009/0130196 A1: bacteriophage composition. 2009.
83. Chibani-Chennoufi, S., Sidoti, J., Bruttin, A., Kutter, E., Sarker, S., Bru, H., In vitro and in vivo bacteriolytic activities of Escherichia coli phages: implications for phage therapy. Antimicrob Agents Chemother 48 (2004), 2558–2569, 10.1128/AAC.48.7.2558.
84. Delbruck, M., The growth of bacteriophage and lysis of the host. J Gen Physiol 23 (1940), 643–660.
85. Abedon, S.T., Lysis from without. Bacteriophage 1 (2011), 46–49, 10.4161/bact.1.1.13980.
86. Denou, E., Bruttin, A., Barretto, C., Ngom-Bru, C., Brüssow, H., Zuber, S., T4 phages against Escherichia coli diarrhea: potential and problems. Virology 388 (2009), 21–30, 10.1016/j.virol.2009.03.009.
87. Schmerer, M., Molineux, I.J., Bull, J.J., Synergy as a rationale for phage therapy using phage cocktails. PeerJ, 2, 2014, e590, 10.7717/peerj.590.
88. Vandenheuvel, D., Lavigne, R., Brussow, H., Bacteriophage therapy: advances in forumulation strategies and human clinical trials. Annu Rev Virol 2 (2015), 599–618.
89. Kucharewicz-Krukowska, A., Slopek, S., Immunogenic effect of bactriophage in patients subjected to phage therapy. Arch Immunol Ther Exp (Warsz) 35 (1987), 553–561.
90. Huff, W.E., Huff, G.R., Rath, N.C., Balog, J.M., Donoghue, A.M., Prevention of Escherichia coli infection in broiler chickens with a bacteriophage aerosol spray. Poult Sci 81 (2002), 1486–1491, 10.1093/ps/81.10.1486.
91. Semler, D.D., Goudie, A.D., Finlay, W.H., Dennis, J.J., Aerosol phage therapy efficacy in Burkholderia cepacia complex respiratory infections. Antimicrob Agents Chemother 58 (2014), 4005–4013, 10.1128/AAC.02388-13.
92. Oliveira, A., Sereno, R., Nicolau, A., Azeredo, J., The influence of the mode of administration in the dissemination of three coliphages in chickens. Poult Sci 88 (2009), 728–733, 10.3382/ps.2008-00378.
93. Cano, V., March, C., Insua, J.L., Aguiló, N., Llobet, E., Moranta, D. et al., Klebsiella pneumoniae survives within macrophages by avoiding delivery to lysosomes. Cell Microbiol 17 (2015), 1537–1560, 10.1111/cmi.12466.
94. Fumagalli, O., Tall, B.D., Schipper, C., Oelschlaeger, T.A., N-glycosylated proteins are involved in efficient internalization of Klebsiella pneumoniae by cultured human epithelial cells. Infect Immun 65 (1997), 4445–4451.
95. Singla, S., Harjai, K., Katare, O.P., Chhibber, S., Encapsulation of bacteriophage in liposome accentuates its entry in to macrophage and shields it from neutralizing antibodies. PLoS One, 11, 2016, e0153777, 10.1371/journal.pone.0153777.
96. Fish, R., Kutter, E., Wheat, G., Blasdel, B., Kutateladze, M., Kuhl, S., Bacteriophage treatment of intransigent diabetic toe ulcers: a case series. J Wound Care 25 (2016), S27–S33.
97. Wright, A., Hawkins, C.H., Änggård, E.E., Harper, D.R., A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy. Clin Otolaryngol 34 (2009), 349–357, 10.1111/j.1749-4486.2009.01973.x.
98. Merabishvili, M., Pirnay, J., Verbeken, G., Chanishvili, N., Tediashvili, M., Lashkhi, N. et al., Quality-controlled small-scale production of a well-defined bacteriophage cocktail for use in human clinical trials. PLoS One 4 (2009), 1–10.
99. Rose, T., Verbeken, G., De Vos, D., Merabishvili, M., Vaneechoutte, M., Jennes, S. et al., Experimental phage therapy of burn wound infection: difficult first steps. Int J Burn Trauma 4 (2014), 66–73.
100. Puapermpoonsiri, U., Spencer, J., van der Walle, C.F., A freeze-dried formulation of bacteriophage encapsulated in biodegradable microspheres. Eur J Pharm Biopharm 72 (2009), 26–33, 10.1016/j.ejpb.2008.12.001.
101. Lee, S.W., Belcher, A.M., Virus-based fabrication of micro- and nanofibers using electrospinning. Nano Lett 4 (2004), 387–390, 10.1021/nl034911t.
102. Briers, Y., Miroshnikov, K., Chertkov, O., Nekrasov, A., Mesyanzhinov, V., Volckaert, G. et al., The structural peptidoglycan hydrolase gp181 of bacteriophage phiKZ. Biochem Biophys Res Commun 374 (2008), 747–751, 10.1016/j.bbrc.2008.07.102.
103. Knezevic, P., Obreht, D., Curcin, S., Petrusic, M., Aleksic, V., Kostanjsek, R. et al., Phages of Pseudomonas aeruginosa: response to environmental factors and in vitro ability to inhibit bacterial growth and biofilm formation. J Appl Microbiol 111 (2011), 245–254, 10.1111/j.1365-2672.2011.05043.x.
104. Leung, S.S.Y., Parumasivam, T., Gao, F.G., Carrigy, N.B., Vehring, R., Finlay, W.H. et al., Production of inhalation phage powders using spray freeze drying and spray drying techniques for treatment of respiratory infections. Pharm Res 33 (2016), 1486–1496, 10.1007/s11095-016-1892-6.
105. Dini, C., de Urraza, P.J., Effect of buffer systems and disaccharides concentration on Podoviridae coliphage stability during freeze drying and storage. Cryobiology 66 (2013), 339–342, 10.1016/j.cryobiol.2013.03.007.
106. Korehei, R., Kadla, J., Incorporation of T4 bacteriophage in electrospun fibres. J Appl Microbiol 114 (2013), 1425–1434, 10.1111/jam.12158.
107. Clark, W.A., Comparison of several methods for preserving bacteriophages. Appl Environ Microbiol 10 (1962), 466–471.
108. Davies, J.D., Kelly, M.J., The preservation of bacteriophage H1 of Corynebacterium ulcerans U103 by freeze-drying. J Hyg (Lond) 67 (1969), 573–583, 10.1017/S0022172400042030.
109. Ackermann, H.-W., Tremblay, D., Moineau, S., Long-term bacteriophage preservation. WFCC Newsl 38 (2004), 35–40.
110. Wang, W., Lyophilization and development of solid protein pharmaceuticals. vol. 203, 2000, 10.1016/S0378-5173(00)00423-3.
111. Abdelwahed, W., Degobert, G., Stainmesse, S., Fessi, H., Freeze-drying of nanoparticles: formulation, process and storage considerations. Adv Drug Deliv Rev 58 (2006), 1688–1713, 10.1016/j.addr.2006.09.017.
112. Telko, M.J., Hickey, A.J., Dry powder inhaler formulation. Respir Care 50 (2005), 1209–1227, 10.2165/00128413-200615470-00016.
113. Engel, H.W.B., Smith, D., Berwald, L.G., The preservation of mycobacteriophages by means of freeze drying. Am Rev Respir Dis 109 (1974), 561–566.
114. Merabishvili, M., Vervaet, C., Pirnay, J.P., de Vos, D., Verbeken, G., Mast, J. et al., Stability of Staphylococcus aureus phage ISP after freeze-drying (lyophilization). PLoS One 8 (2013), 1–7, 10.1371/journal.pone.0068797.
115. Malenovská, H., The influence of stabilizers and rates of freezing on preserving of structurally different animal viruses during lyophilization and subsequent storage. J Appl Microbiol 117 (2014), 1810–1819, 10.1111/jam.12654.
116. Golshahi, L., Lynch, K.H., Dennis, J.J., Finlay, W.H., In vitro lung delivery of bacteriophages KS4-M and φKZ using dry powder inhalers for treatment of Burkholderia cepacia complex and Pseudomonas aeruginosa infections in cystic fibrosis. J Appl Microbiol 110 (2010), 106–117, 10.1111/j.1365-2672.2010.04863.x.
117. Puapermpoonsiri, U., Ford, S.J., van der Walle, C.F., Stabilization of bacteriophage during freeze drying. Int J Pharm 389 (2010), 168–175, 10.1016/j.ijpharm.2010.01.034.
118. Dai, M., Senecal, A., Nugen, S.R., Electrospun water-soluble polymer nanofibers for the dehydration and storage of sensitive reagents. Nanotechnology, 25, 2014, 225101, 10.1088/0957-4484/25/22/225101.
119. Cox, C.S., Harris, W.J., Lee, J., Viability and electron microscope studies of phages T3 and T7 subjected to freeze-drying, freeze-thawing and aerosolization. J Gen Microbiol 81 (1974), 207–215.
120. Leung, S.S.Y., Parumasivam, T., Gao, F.G., Carrigy, N.B., Vehring, R., Finlay, W.H. et al., Effects of storage conditions on the stability of spray dried, inhalable bacteriophage powders. Int J Pharm, 2017, 10.1016/j.ijpharm.2017.01.060.
121. Markoishvili, K., Tsitlanadze, G., Katsarava, R., Morris, J.G., Sulakvelidze, A., A novel sustained-release matrix based on biodegradable poly(ester amide)s and impregnated with bacteriophages and an antibiotic shows promise in management of infected venous stasis ulcers and other poorly healing wounds. Int J Dermatol 41 (2002), 453–458.
122. Dini, C., Islan, G.A., de Urraza, P.J., Castro, G.R., Novel biopolymer matrices for microencapsulation of phages: enhanced protection against acidity and protease activity. Macromol Biosci 12 (2012), 1200–1208, 10.1002/mabi.201200109.
123. Alfadhel, M., Puapermpoonsiri, U., Ford, S.J., McInnes, F.J., Van Der Walle, C.F., Lyophilized inserts for nasal administration harboring bacteriophage selective for Staphylococcus aureus: in vitro evaluation. Int J Pharm 416 (2011), 280–287, 10.1016/j.ijpharm.2011.07.006.
124. Hoe, S., Ivey, J.W., Boraey, M.A., Shamsaddini-Shahrbabak, A., Javaheri, E., Matinkhoo, S. et al., Use of a fundamental approach to spray-drying formulation design to facilitate the development of multi-component dry powder aerosols for respiratory drug delivery. Pharm Res 31 (2014), 449–465, 10.1007/s11095-013-1174-5.
125. Chew, N.Y.K., Chan, H.K., The role of particle properties in pharmaceutical powder inhalation formulations. J Aerosol Med 15 (2002), 325–330.
126. Klingler, C., Müller, B.W., Steckel, H., Insulin-micro- and nanoparticles for pulmonary delivery. Int J Pharm 377 (2009), 173–179, 10.1016/j.ijpharm.2009.05.008.
127. Weers, J., Inhaled antimicrobial therapy - barriers to effective treatment. Adv Drug Deliv Rev 85 (2015), 24–43, 10.1016/j.addr.2014.08.013.
128. Vandenheuvel, D., Singh, A., Vandersteegen, K., Klumpp, J., Lavigne, R., Van Den Mooter, G., Feasibility of spray drying bacteriophages into respirable powders to combat pulmonary bacterial infections. Eur J Pharm Biopharm 84 (2013), 578–582, 10.1016/j.ejpb.2012.12.022.
129. Jończyk, E., Kłak, M., Międzybrodzki, R., Górski, A., The influence of external factors on bacteriophages—review. Folia Microbiol (Praha) 56 (2011), 191–200, 10.1007/s12223-011-0039-8.
130. Walbeck, A.K., US20138501453B2: methods for drying bacteriophage and bacteriophage-containing compositions, the resulting dry compositions, and methods of use. 2013.
131. Matinkhoo, S., Lynch, K.H., Dennis, J.J., Finlay, W.H., Vehring, R., Spray-dried respirable powders containing bacteriophages for the treatment of pulmonary infections. J Pharm Sci 100 (2011), 5197–5205.
132. Vandenheuvel, D., Meeus, J., Lavigne, R., Van Den Mooter, G., Instability of bacteriophages in spray-dried trehalose powders is caused by crystallization of the matrix. Int J Pharm 472 (2014), 202–205, 10.1016/j.ijpharm.2014.06.026.
133. Crowe, L.M., Reid, D.S., Crowe, J.H., Is trehalose special for preserving dry biomaterials?. Biophys J 71 (1996), 2087–2093, 10.1016/S0006-3495(96)79407-9.
134. Steckel, H., Bolzen, N., Alternative sugars as potential carriers for dry powder inhalations. Int J Pharm 270 (2004), 297–306, 10.1016/j.ijpharm.2003.10.039.
135. Walbeck, A.K., US 2009/0093041 A1. Methods for drying bacteriophage and bacteriophage containing compositions, the resulting dry compositions, and methods of use, 2009.
136. Wong, Y.-L., Sampson, S., Germishuizen, W.A., Goonesekera, S., Caponetti, G., Sadoff, J. et al., Drying a tuberculosis vaccine without freezing. Proc Natl Acad Sci U S A 104 (2007), 2591–2595, 10.1073/pnas.0611430104.
137. Sahota, J.S., Smith, C.M., Radhakrishnan, P., Winstanley, C., Goderdzishvili, M., Chanishvili, N. et al., Bacteriophage delivery by nebulization and efficacy against phenotypically diverse Pseudomonas aeruginosa from cystic fibrosis patients. J Aerosol Med Pulm Drug Deliv 28 (2015), 353–360, 10.1089/jamp.2014.1172.
138. Golshahi, L., Seed, K.D., Dennis, J.J., Finlay, W.H., Toward modern inhalational bacteriophage therapy: nebulization of bacteriophages of Burkholderia cepacia complex. J Aerosol Med Pulm Drug Deliv 21 (2008), 351–360, 10.1089/jamp.2008.0701.
139. Prouty, C.C., Storage of the bacteriophage of the lactic acid streptococci in the desiccated state with observations on longevity. Appl Microbiol 1 (1953), 250–251.
140. Ibekwe, V.C., Fadda, H.M., McConnell, E.L., Khela, M.K., Evans, D.F., Basit, A.W., Interplay between intestinal pH, transit time and feed status on the in vivo performance of pH responsive ileo-colonic release systems. Pharm Res 25 (2008), 1828–1835, 10.1007/s11095-008-9580-9.
141. McConnell, E.L., Fadda, H.M., Basit, A.W., Gut instincts: explorations in intestinal physiology and drug delivery. Int J Pharm 364 (2008), 213–226, 10.1016/j.ijpharm.2008.05.012.
142. Esteban, P.P., Alves, D.R., Enright, M.C., Bean, J.E., Gaudion, A., Jenkins, A.T.A. et al., Enhancement of the antimicrobial properties of bacteriophage-K via stabilization using oil-in-water nano-emulsions. Biotechnol Prog 30 (2014), 932–944, 10.1002/btpr.1898.
143. Ma, Y., Pacan, J.C., Wang, Q., Xu, Y., Huang, X., Korenevsky, A. et al., Microencapsulation of bacteriophage Felix O1 into chitosan-alginate microspheres for oral delivery. Appl Environ Microbiol 74 (2008), 4799–4805, 10.1128/AEM.00246-08.
144. Gul, O., Dervisoglu, M., Application of multicriteria decision technique to determine optimum sodium alginate concentration for microencapsulation of Lactobacillus casei Shirota by extrusion and emulsification. J Food Process Eng 40 (2017), 1–10, 10.1111/jfpe.12481.
145. Ma, Y., Pacan, J.C., Wang, Q., Sabour, P.M., Huang, X., Xu, Y., Enhanced alginate microspheres as means of oral delivery of bacteriophage for reducing Staphylococcus aureus intestinal carriage. Food Hydrocoll 26 (2012), 434–440, 10.1016/j.foodhyd.2010.11.017.
146. Lotfipour, F., Mirzaeei, S., Maghsoodi, M., Preparation and characterization of alginate and psyllium beads containing Lactobacillus acidophilus. ScientificWorldJournal, 2012, 2012, 680108, 10.1100/2012/680108.
147. Hathaway, H., Alves, D.R., Bean, J., Esteban, P.P., Ouadi, K., Sutton, J.M. et al., Poly (N-isopropylacrylamide-co-allylamine) (PNIPAM-co-ALA) nanospheres for the thermally triggered release of Bacteriophage K. Eur J Pharm Biopharm 96 (2015), 437–441, 10.1016/j.ejpb.2015.09.013.
148. Bean, J.E., Alves, D.R., Laabei, M., Esteban, P.P., Thet, N.T., Enright, M.C. et al., Triggered release of bacteriophage K from agarose/hyaluronan hydrogel matrixes by Staphylococcus aureus virulence factors. Chem Mater 26 (2014), 7201–7208.
149. Samtlebe, M., Ergin, F., Wagner, N., Neve, H., Küçükçetin, A., Franz, C.M.A.P. et al., Carrier systems for bacteriophages to supplement food systems: encapsulation and controlled release to modulate the human gut microbiota. LWT- Food Sci Technol 68 (2016), 334–340, 10.1016/j.lwt.2015.12.039.
150. Nieth, A., Verseux, C., Barnert, S., Süss, R., Römer, W., Nieth, A. et al., A first step toward liposome-mediated intracellular bacteriophage therapy. Expert Opin Drug Deliv 12 (2015), 1411–1424, 10.1517/17425247.2015.1043125.
151. Kuhn, J.C., Zussman, E., US 2009/0061496A1. Encapsulation of bacteria and viruses in electrospun fibers, 2009.
152. Salalha, W., Kuhn, J., Dror, Y., Zussman, E., Encapsulation of bacteria and viruses in electrospun nanofibres. Nanotechnology 17 (2006), 4657–4681, 10.1088/0957-4484/17/18/025.
153. Korehei, R., Kadla, J.F., Encapsulation of T4 bacteriophage in electrospun poly(ethylene oxide)/cellulose diacetate fibers. Carbohydr Polym 100 (2014), 150–157, 10.1016/j.carbpol.2013.03.079.
154. Vonasek, E., Le, P., Nitin, N., Encapsulation of bacteriophages in whey protein films for extended storage and release. Food Hydrocoll 37 (2014), 7–13, 10.1016/j.foodhyd.2013.09.017.
155. Lone, A., Anany, H., Hakeem, M., Aguis, L., Avdjian, A.C., Bouget, M. et al., Development of prototypes of bioactive packaging materials based on immobilized bacteriophages for control of growth of bacterial pathogens in foods. Int J Food Microbiol 217 (2016), 49–58, 10.1016/j.ijfoodmicro.2015.10.011.
156. Kaikabo, A.A., AbdulKarim, S.M., Abas, F., Evaluation of the efficacy of chitosan nanoparticles loaded FKAZ14 bacteriophage in the biological control of colibacillosis in chickens. Poult Sci 96 (2017), 295–302, 10.3382/ps/pew255.
157. Tang, Z., Huang, X., Baxi, S., Chambers, J.R., Sabour, P.M., Wang, Q., Whey protein improves survival and release characteristics of bacteriophage Felix O1 encapsulated in alginate microspheres. Food Res Int 52 (2013), 460–466, 10.1016/j.foodres.2012.12.037.
158. Kim, S., Jo, A., Ahn, J., Application of chitosan–alginate microspheres for the sustained release of bacteriophage in simulated gastrointestinal conditions. Int J Food Sci Technol 50 (2015), 913–918, 10.1111/ijfs.12736.
159. Tang, Z., Huang, X., Sabour, P.M., Chambers, J.R., Wang, Q., Preparation and characterization of dry powder bacteriophage K for intestinal delivery through oral administration. LWT- Food Sci Technol 60 (2015), 263–270, 10.1016/j.lwt.2014.08.012.
160. Katsarava, R., Alavidze, Z., US6703040B2: polymer blends as boidegradable matrices for preparing biocomposites. 2004.
161. Govender, M., Choonara, Y.E., Van Vuuren, S., Kumar, P., Du Toit, L.C., Pillay, V.A., A gastro-resistant ovalbumin bi-layered mini-tablet-in-tablet system for the delivery of Lactobacillus acidophilus probiotic to simulated human intestinal and colon conditions. J Pharm Pharmacol 67 (2015), 939–950, 10.1111/jphp.12389.
162. Katsarava, R., Beridze, V., Arabuli, N., Kharadze, D., Chu, C.C., Won, C.Y., Amino Acid-Based Bioanalogous Polymers. Synthesis, and Study of Regular Poly(ester amide)s Based on Bis(alpha-amino acid) alpha,omega-Alkylene Diesters, and Aliphatic Dicarboxylic Acids. J Polym Sci: Part A: Polym Chem 37 (1999), 391–407.
163. Davis, S.S., Hardy, J.G., Fara, J.W., Transit of pharmaceutical dosage forms through the small intestine. Gut 27 (1986), 886–892, 10.1136/gut.27.8.886.
164. Davis, S.S., Illum, L., Hinchcliffe, M., Gastrointestinal transit of dosage forms in the pig. J Pharm Pharmacol 53 (2001), 33–39, 10.1211/0022357011775163.
165. Uriot, O., Galia, W., Awussi, A.A., Perrin, C., Denis, S., Chalancon, S. et al., Use of the dynamic gastro-intestinal model TIM to explore the survival of the yogurt bacterium Streptococcus thermophilus and the metabolic activities induced in the simulated human gut. Food Microbiol 53 (2016), 18–29, 10.1016/j.fm.2015.05.007.
166. Philip, A.K., Philip, B., Colon targeted drug delivery systems: a review on primary and novel approaches. Oman Med J 25 (2010), 79–87, 10.5001/omj.2010.24.
167. Choonara, B.F., Choonara, Y.E., Kumar, P., Bijukumar, D., du Toit, L.C., Pillay, V., A review of advanced oral drug delivery technologies facilitating the protection and absorption of protein and peptide molecules. Biotechnol Adv 32 (2014), 1269–1282, 10.1016/j.biotechadv.2014.07.006.
168. Amidon, S., Brown, J.E., Dave, V.S., Colon-targeted oral drug delivery systems: design trends and approaches. AAPS PharmSciTech 16 (2015), 731–741, 10.1208/s12249-015-0350-9.
169. Van Citters, G.W., Lin, H.C., Ileal brake: neuropeptidergic control of intestinal transit. Curr Gastroenterol Rep 8 (2006), 367–373, 10.1007/s11894-006-0021-9.
170. Hua, S., Marks, E., Schneider, J.J., Keely, S., Advances in oral nano-delivery systems for colon targeted drug delivery in inflammatory bowel disease: selective targeting to diseased versus healthy tissue. Nanomed Nanotechnol Biol Med 11 (2015), 1117–1132, 10.1016/j.nano.2015.02.018.
171. Brayden, D.J., Jepson, M.A., Baird, A.W., Intestinal Peyer's patch M cells and oral vaccine targeting. Drug Discov Today 10 (2005), 1145–1157, 10.1016/S1359-6446(05)03536-1.
172. Inman, L.R., Cantey, J.R., Specific adherence of Escherichia coli (strain RDEC-1) to membranous (M) cells of the Peyer's patch in Escherichia coli diarrhea in the rabbit. J Clin Invest 71 (1983), 1–8, 10.1172/JCI110737.
173. Pappo, J., Ermak, T.H., Steger, H.J., Monoclonal antibody-directed targeting of fluorescent polystyrene microspheres to Peyer's patch M cells. Immunology 73 (1991), 277–280.
174. Shakweh, M., Ponchel, G., Fattal, E., Particle uptake by Peyer's patches: a pathway for drug and vaccine delivery. Expert Opin Drug Deliv 1 (2005), 141–163.
175. George, M., Abraham, T.E., Polyionic hydrocolloids for the intestinal delivery of protein drugs: alginate and chitosan - a review. J Control Release 114 (2006), 1–14, 10.1016/j.jconrel.2006.04.017.
176. Ensign, L.M., Cone, R., Hanes, J., Oral drug delivery with polymeric nanoparticles: the gastrointestinal mucus barriers. Adv Drug Deliv Rev 64 (2012), 557–570, 10.1016/j.addr.2011.12.009.
177. Lai, S.K., Wang, Y.Y., Hanes, J., Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. Adv Drug Deliv Rev 61 (2009), 158–171, 10.1016/j.addr.2008.11.002.
178. Jain, D., Panda, A.K., Majumdar, D.K., Eudragit S100 entrapped insulin microspheres for oral delivery. AAPS PharmSciTech 6 (2005), E100–E107, 10.1208/pt060116.
179. Silva, C.M., Ribeiro, A.J., Ferreira, D., Veiga, F., Insulin encapsulation in reinforced alginate microspheres prepared by internal gelation. Eur J Pharm Sci 29 (2006), 148–159, 10.1016/j.ejps.2006.06.008.
180. Kietzmann, D., Moulari, B., Béduneau, A., Pellequer, Y., Lamprecht, A., Colonic delivery of carboxyfluorescein by pH-sensitive microspheres in experimental colitis. Eur J Pharm Biopharm 76 (2010), 290–295, 10.1016/j.ejpb.2010.06.013.
181. Chawla, A., Sharma, P., Pawar, P., Eudragit S-100 coated sodium alginate microspheres of naproxen sodium: formulation, optimization and in vitro evaluation. Acta Pharm 62 (2012), 529–545, 10.2478/v10007-012-0034-x.
182. De Arce, Velasquez A., Ferreira, L.M., Stangarlin, M.F.L., Da Silva, C.D.B., Rolim, C.M.B., Cruz, L., Novel Pullulan-Eudragit S100 blend microparticles for oral delivery of risedronate: formulation, in vitro evaluation and tableting of blend microparticles. Mater Sci Eng C 38 (2014), 212–217, 10.1016/j.msec.2014.02.003.
183. Stuart, M. a C., WTS, Huck, Genzer, J., Müller, M., Ober, C., Stamm, M. et al., Emerging applications of stimuli-responsive polymer materials. Nat Mater 9 (2010), 101–113, 10.1038/nmat2614.
184. Lautenschläger, C., Schmidt, C., Fischer, D., Stallmach, A., Drug delivery strategies in the therapy of inflammatory bowel disease. Adv Drug Deliv Rev 71 (2014), 58–76, 10.1016/j.addr.2013.10.001.
185. de Souza, D.F., Goebel, K., Andreazza, I.F., Development of enteric coated sustained release minitablets containing mesalamine. Braz J Pharm Sci 49 (2013), 529–536, 10.1590/S1984-82502013000300014.
186. Sekirov, I., Russell, S., Antunes, L., Gut microbiota in health and disease. Physiol Rev 90 (2010), 859–904, 10.1152/physrev.00045.2009.
187. Nicholson, J.K., Holmes, E., Kinross, J., Burcelin, R., Gibson, G., Jia, W. et al., Host-Gut microbiota metabolic interactions. Science 336 (2012), 1262–1268.
188. Mountzouris, K.C., Tsirtsikos, P., Kalamara, E., Nitsch, S., Schatzmayr, G., Fegeros, K., Evaluation of the efficacy of a probiotic containing Lactobacillus, Bifidobacterium, Enterococcus, and Pediococcus strains in promoting broiler performance and modulating cecal microflora composition and metabolic activities. Poult Sci 86 (2007), 309–317.
189. Hovgaard, L., Brondsted, H., Current applications of polysaccharides in colon targeting. Crit Rev Ther Drug Carrier Syst 13 (1996), 185–223.
190. Vandamme, T.F., Lenourry, A., Charrueau, C., Chaumeil, J.C., The use of polysaccharides to target drugs to the colon. Carbohydr Polym 48 (2002), 219–231, 10.1016/S0144-8617(01)00263-6.
191. Lorenzo-Lamosa, M.L., Remuñán-López, C., Vila-Jato, J.L., Alonso, M.J., Design of microencapsulated chitosan microspheres for colonic drug delivery. J Control Release 52 (1998), 109–118, 10.1016/S0168-3659(97)00203-4.
192. Calinescu, C., Mateescu, M.A., Carboxymethyl high amylose starch: chitosan self-stabilized matrix for probiotic colon delivery. Eur J Pharm Biopharm 70 (2008), 582–589, 10.1016/j.ejpb.2008.06.006.
193. Bernkop-Schnürch, A., Humenberger, C., Valenta, C., Basic studies on bioadhesive delivery systems for peptide and protein drugs. Int J Pharm 165 (1998), 217–225, 10.1016/S0378-5173(98)00017-9.
194. Thanou, M., Verhoef, J.C., Junginger, H.E., Chitosan and its derivatives as intestinal absorption enhancers. Adv Drug Deliv Rev 50 (2001), 91–101, 10.1016/S0169-409X(01)00180-6.
195. Van der Lubben, I.M., Verhoef, J.C., Borchard, G., Junginger, H.E., Chitosan and its derivatives in mucosal drug and vaccine delivery. Eur J Pharm Sci 14 (2001), 201–207, 10.1016/S0928-0987(01)00172-5.
196. Lameiro, M.H., Malpique, R., Silva, A.C., Alves, P.M., Melo, E., Encapsulation of adenoviral vectors into chitosan-bile salt microparticles for mucosal vaccination. J Biotechnol 126 (2006), 152–162, 10.1016/j.jbiotec.2006.04.030.
197. Takeuchi, H., Matsui, Y., Sugihara, H., Yamamoto, H., Kawashima, Y., Effectiveness of submicron-sized, chitosan-coated liposomes in oral administration of peptide drugs. Int J Pharm 303 (2005), 160–170, 10.1016/j.ijpharm.2005.06.028.
198. Thirawong, N., Thongborisute, J., Takeuchi, H., Sriamornsak, P., Improved intestinal absorption of calcitonin by mucoadhesive delivery of novel pectin-liposome nanocomplexes. J Control Release 125 (2008), 236–245, 10.1016/j.jconrel.2007.10.023.
199. Shi, L., Li, Z., Li, D., Xu, M., Chen, H., Zhang, Z. et al., Encapsulation of probiotic Lactobacillus bulgaricus in alginate–milk microspheres and evaluation of the survival in simulated gastrointestinal conditions. J Food Eng 117 (2013), 99–104, 10.1016/j.jfoodeng.2013.02.012.
200. Matsubara, T., Emoto, W., Kawashiro, K., A simple two-transition model for loss of infectivity of phages on exposure to organic solvent. Biomol Eng 24 (2007), 269–271, 10.1016/j.bioeng.2007.02.002.
201. Olofsson, L., Ankarloo, J., Andersson, P.O., Nicholls, I.A., Filamentous bacteriophage stability in non-aqueous media. Chem Biol 8 (2001), 661–671, 10.1016/S1074-5521(01)00041-2.
202. Waddell, T.E., Johnson, R., Mazzocco, A., US7601347 B2: methods and compositions for controlled release of bioactive compounds. 2009.
203. Milo, S., Thet, N.T., Liu, D., Nzakizwanayo, J., Jones, B.V., Jenkins, A.T.A., An in-situ infection detection sensor coating for urinary catheters. Biosens Bioelectron 81 (2016), 166–172, 10.1016/j.bios.2016.02.059.
204. Weinberger, A., Tsai, F.C., Koenderink, G.H., Schmidt, T.F., Itri, R., Meier, W. et al., Gel-assisted formation of giant unilamellar vesicles. Biophys J 105 (2013), 154–164, 10.1016/j.bpj.2013.05.024.
205. Pautot, S., Frisken, B.J., Weitz, D.A., Engineering asymmetric vesicles. Proc Natl Acad Sci 100 (2003), 10718–10721, 10.1073/pnas.1931005100.
206. Balcao, V.M., Glasser, C.A., Chaud, M.V., del Fiol, F.S., Tubino, M., Vila, M.M.D.C., Biomimetic aqueous-core lipid nanoballoons integrating a multiple emulsion formulation: a suitable housing system for viable lytic bacteriophages. Colloids Surf B Biointerfaces 123 (2014), 478–485, 10.1016/j.colsurfb.2014.09.045.
207. Torchilin, V.P., Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 4 (2005), 145–160, 10.1038/nrd1632.
208. Xiao, B., Laroui, H., Ayyadurai, S., Viennois, E., Charania, M.A., Zhang, Y. et al., Mannosylated bioreducible nanoparticle-mediated macrophage-specific TNF-alpha RNA interference for IBD therapy. Biomaterials 34 (2013), 7471–7482, 10.1016/j.biomaterials.2013.06.008.
209. Pichai, M.V.A., Ferguson, L.R., Potential prospects of nanomedicine for targeted therapeutics in inflammatory bowel diseases. World J Gastroenterol 18 (2012), 2895–2901, 10.3748/wjg.v18.i23.2895.
210. Schmidt, C., Lautenschlaeger, C., Collnot, E.M., Schumann, M., Bojarski, C., Schulzke, J.D. et al., Nano- and microscaled particles for drug targeting to inflamed intestinal mucosa - a first in vivo study in human patients. J Control Release 165 (2013), 139–145, 10.1016/j.jconrel.2012.10.019.
211. Coco, R., Plapied, L., Pourcelle, V., Jérôme, C., Brayden, D.J., Schneider, Y.J. et al., Drug delivery to inflamed colon by nanoparticles: comparison of different strategies. Int J Pharm 440 (2013), 3–12, 10.1016/j.ijpharm.2012.07.017.
212. Cu, Y., Saltzman, W.M., Stealth particles give mucus the slip. Nat Mater 8 (2009), 11–13, 10.1016/j.immuni.2010.12.017.Two-stage.
213. Cu, Y., Saltzman, W.M., Controlled surface modification with poly(ethylene)glycol enhances diffusion of PLGA nanoparticles in human cervical mucus. Mol Pharm 6 (2008), 173–181, 10.1021/mp8001254.
214. Saltzman, W.M., Radomsky, M.L., Whaley, K.J., Cone, R.A., Antibody diffusion in human cervical mucus. Biophys J 66 (1994), 508–515, 10.1016/S0006-3495(94)80802-1.
215. Agrawal, A.K., Gupta, C.M., Tuftsin-bearing liposomes in treatment of macrophage-based infections. Adv Drug Deliv Rev 41 (2000), 135–146, 10.1016/S0169-409X(99)00061-7.
216. Broxmeyer, L., Sosnowska, D., Miltner, E., Chacón, O., Wagner, D., McGarvey, J. et al., Killing of Mycobacterium avium and Mycobacterium tuberculosis by a mycobacteriophage delivered by a nonvirulent Mycobacterium: a model for phage therapy of intracellular bacterial pathogens. J Infect Dis 186 (2002), 1155–1160, 10.1086/343812.
217. Danelishvili, L., Young, L.S., Bermudez, L.E., In vivo efficacy of phage therapy for Mycobacterium avium infection as delivered by a nonvirulent Mycobacterium. Microb Drug Resist 12 (2006), 1–6.
218. Owais, M., Gupta, C.M., Targeted drug delivery to macrophages in parasitic infections. Curr Drug Deliv 2 (2005), 311–318.
219. Orozco, L.C., Quintana, F.O., Beltran, R.M., Moreno, I.D., Wasserman, M., Rodriguez, G., The use of rifampicin and isoniazid entrapped in liposomes for the treatment of murine tuberculosis. Tubercle 67 (1986), 91–97.
220. Roesken, F., Uhl, E., Curri, S.B., Menger, M.D., Messmer, K., Acceleration of wound healing by topical drug delivery via liposomes. Langenbecks Arch Surg 385 (2000), 42–49, 10.1007/s004230050010.
221. Ferreira, H., Matamá, T., Silva, R., Silva, C., Gomes, A.C., Cavaco-Paulo, A., Functionalization of gauzes with liposomes entrapping an anti-inflammatory drug: a strategy to improve wound healing. React Funct Polym 73 (2013), 1328–1334, 10.1016/j.reactfunctpolym.2013.05.012.
222. Yerushalmi, N., Arad, A., Margalit, R., Molecular and cellular studies of hyaluronic acid-modified liposomes as bioadhesive carriers for topical drug delivery in wound healing. Arch Biochem Biophys 313 (1994), 267–273, 10.1006/abbi.1994.1387.
223. Pearson, H.A., Sahukhal, G.S., Elasri, M.O., Urban, M.W., Phage-bacterium war on polymeric surfaces: can surface-anchored bacteriophages eliminate microbial infections?. Biomacromolecules 14 (2013), 1257–1261.
224. Bennett, A.R., Davids, F.G., Vlahodimou, S., Banks, J.G., Betts, R.P., The use of bacteriophage-based systems for the separation and concentration of Salmonella. J Appl Microbiol 83 (1997), 259–265.
225. Sun, W., Brovko, L., Griffiths, M., Food-borne pathogens. Use of bioluminescent Salmonella for assessing the efficiency of constructed phage-based biosorbent y,z. Int J Food Microbiol, 2001, 273–275.
226. Tolba, M., Minikh, O., Brovko, L.Y., Evoy, S., Griffiths, M.W., Oriented immobilization of bacteriophages for biosensor applications. Appl Environ Microbiol 76 (2010), 528–535, 10.1128/AEM.02294-09.
227. Anany, H., Chen, W., Pelton, R., Griffiths, M.W., Biocontrol of Listeria monocytogenes and Escherichia coli O157:H7 in meat by using phages immobilized on modified cellulose membranes. Appl Environ Microbiol 77 (2011), 6379–6387, 10.1128/AEM.05493-11.
228. Donlan, R.M., Lehman, S.M., Garcia, A.J., US9457132B2: controlled covalent attachment of bioactive bacteriophage for regulating biofilm development. 2016.
229. Scott, H., Mattey, M., WO2003093462A2: immobilisation and stabilisation of virus. 2003.
230. Cooper, I.R., Illsley, M., Korobeinyk, A.V., Whitby, R.L.D., Bacteriophage-nanocomposites: an easy and reproducible method for the construction, handling, storage and transport of conjugates for deployment of bacteriophages active against Pseudomonas aeruginosa. J Microbiol Methods 111 (2015), 111–118, 10.1016/j.mimet.2015.02.005.
231. Handa, H., Gurczynski, S., Jackson, M.P., Auner, G., Walker, J., Mao, G., Recognition of Salmonella typhimurium by immobilized phage P22 monolayers. Surf Sci 602 (2008), 1392–1400, 10.1016/j.susc.2008.01.036.
232. Singh, A., Glass, N., Tolba, M., Brovko, L., Griffiths, M., Evoy, S., Immobilization of bacteriophages on gold surfaces for the specific capture of pathogens. Biosens Bioelectron 24 (2009), 3645–3651, 10.1016/j.bios.2009.05.028.
233. Yang, L.C., Tam, P.Y., Murray, B.J., Mcintire, T.M., Overstreet, C.M., Weiss, G.A. et al., Virus electrodes for universal biodetection. Anal Chem 78 (2006), 3265–3270.
234. Richter, Å., Matuła, K., Lesniewski, A., Kwasnicka, K., Łos, J., Łos, M. et al., Ordering of bacteriophages in the electric field: application for bacteria detection. Sens Actuators B 224 (2016), 233–240, 10.1002/9780470015902.a0024053.
235. Tawil, N., Sacher, E., Rioux, D., Mandeville, R., Meunier, M., Surface chemistry of bacteriophage and laser ablated nanoparticle complexes for pathogen detection. J Phys Chem C 119 (2015), 14375–14382, 10.1021/acs.jpcc.5b02169.
236. Vladisavljevic, G.T., Williams, R.A., Recent developments in manufacturing emulsions and particulate products using membranes. Adv Colloid Interface Sci 113 (2005), 1–20, 10.1016/j.cis.2004.10.002.
237. Kukizaki, M., Shirasu porous glass (SPG) membrane emulsification in the absence of shear flow at the membrane surface: influence of surfactant type and concentration, viscosities of dispersed and continuous phases, and transmembrane pressure. J Membr Sci 327 (2009), 234–243, 10.1016/j.memsci.2008.11.026.
238. Vladisavljević, G.T., Kobayashi, I., Nakajima, M., Production of uniform droplets using membrane, microchannel and microfluidic emulsification devices. Microfluid Nanofluid 13 (2012), 151–178, 10.1007/s10404-012-0948-0.
239. Kosvintsev, S.R., Gasparini, G., Holdich, R.G., Cumming, I.W., Stillwell, M.T., Liquid-liquid membrane dispersion in a stirred cell with and without controlled shear. Ind Eng Chem Res 44 (2005), 9323–9330.
240. Vladisavljević, G.T., Williams, R.A., Manufacture of large uniform droplets using rotating membrane emulsification. J Colloid Interface Sci 299 (2006), 396–402, 10.1016/j.jcis.2006.01.061.
241. Holdich, R.G., Dragosavac, M.M., Vladisavljević, G.T., Kosvintsev, S.R., Membrane emulsification with oscillating and stationary membranes. Ind. Eng. Chem. Res. 49 (2010), 3810–3817, 10.1021/ie900531n.
242. Silva, P.S., Dragosavac, M.M., Vladisavljevic, G.T., Bandulasena, H.C.H., Holdich, R.G., Stillwell, M. et al., Azimuthally oscillating membrane emulsification for controlled droplet production. AIChE J 61 (2015), 3607–3615, 10.1002/aic.
243. Anna, S.L., Droplets and bubbles in microfluidic devices. Annu Rev Fluid Mech 48 (2016), 285–309, 10.1146/annurev-fluid-122414-034425.
244. Engl, W., Backov, R., Panizza, P., Controlled production of emulsions and particles by milli- and microfluidic techniques. Curr Opin Colloid Interface Sci 13 (2008), 206–216, 10.1016/j.cocis.2007.09.003.
245. Yobas, L., Martens, S., Ong, W.-L., Ranganathan, N., High-performance flow-focusing geometry for spontaneous generation of monodispersed droplets. Lab Chip 6 (2006), 1073–1079, 10.1039/b602240e.
246. Chu, L.Y., Utada, A.S., Shah, R.K., Kim, J.W., Weitz, D.A., Controllable monodisperse multiple emulsions. Angew Chem Int Ed 46 (2007), 8970–8974, 10.1002/anie.200701358.
247. Wang, W., Xie, R., Ju, X.-J., Luo, T., Liu, L., Weitz, D.A. et al., Controllable microfluidic production of multicomponent multiple emulsions. Lab Chip 11 (2011), 1587–1592, 10.1039/c1lc20065h.
248. Abate, A.R., Weitz, D.A., High-order multiple emulsions formed in poly(dimethylsiloxane) microfluidics. Small 5 (2009), 2030–2032, 10.1002/smll.200900569.
249. Kim, S.H., Weitz, D.A., One-step emulsification of multiple concentric shells with capillary microfluidic devices. Angew Chem Int Ed 50 (2011), 8731–8734, 10.1002/anie.201102946.
250. Yang, S., Guo, F., Kiraly, B., Mao, X., Lu, M., Leong, K.W. et al., Microfluidic synthesis of multifunctional Janus particles for biomedical applications. Lab Chip, 12, 2012, 2097, 10.1039/c2lc90046g.
251. Nie, Z., Li, W., Seo, M., Xu, S., Kumacheva, E., Janus and ternary particles generated by microfluidic synthesis: design, synthesis, and self-assembly. J Am Chem Soc 128 (2006), 9408–9412, 10.1021/ja060882n.